News

In exchange for the technology, BioSante received a 19.9% ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and

The updated data showed that the median time to progression for patients receiving Zybrestat plus bevacizumab and chemotherapy was 9.5 months, compared with a median time to progression

In the trial, patients received a recommended dose of 267mg/m2 by intravenous infusion over 2 hours, with retreatment every 3 weeks, for up to 6 courses. Aeterna Zentaris

Under the Department of Defense Prostate Cancer Research Program (PCRP) of the Office of the Congressionally Directed Medical Research Programs (CDMRP), STA-9584 is approved for funding of approximately

The Hyderabad-based Aurobindo Pharma is expected to sign an agreement regarding this with Pfizer, reported The Financial Express. Currently, Aurobindo is in pact with Pfizer for the marketing

Under the terms of their partnership agreement signed in January 2010, Inspiration in-licensed OBI-1 from Ipsen, and is responsible for the clinical development, regulatory process and commercialisation of

The first product in the new line is Allegro CTMS@Site, the clinical trials management system built exclusively for investigational sites. Forte Research claimed that the Allegro product line

Under terms of the agreement, Cardium will identify a line of products applying BioZone technology such as that incorporated into its QuSome, Inflacin, LipoCeutical, LipoSpray and other formulation

Agennix has posted a net loss of EUR11.2m for the third quarter 2010, or EUR0.54 loss per diluted share, compared to net loss of EUR2.14m, or EUR0.29 loss